Medicenna Therapeutics (TSX:MDNA) - Hisse Senedi Fiyatı, Haberler ve Analizler

MDNA Stoklara Genel Bakış

MDNA temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançların yılda 57.2% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( CA$0 )

Hissedarlar geçen yıl sulandırıldı

Medicenna Therapeutics Corp. Rakipler

Eupraxia Pharmaceuticals

TSX:EPRX

CA$157.8m

Bright Minds Biosciences

CNSX:DRUG

CA$334.4m

Oncolytics Biotech

TSX:ONC

CA$125.6m

Covalon Technologies

TSXV:COV

CA$93.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Medicenna Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$2.41
52 Haftanın En Yüksek Seviyesi	CA$2.98
52 Haftanın En Düşük Seviyesi	CA$0.38
Beta	1.21
11 Aylık Değişim	15.31%
3 Aylık Değişim	10.55%
1 Yıllık Değişim	386.87%
33 Yıllık Değişim	-2.82%
5 Yıllık Değişim	77.21%
Halka arzdan bu yana değişim	-10.74%

Son Haberler & Güncellemeler

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Hissedar Getirileri

	MDNA	CA Biotechs	CA Pazar
7D	4.3%	4.4%	0.2%
1Y	386.9%	13.3%	24.4%

Getiri vs. Endüstri: MDNA geçen yıl % 13.3 oranında getiri sağlayan Canadian Biotechs sektörünü aştı.

Getiri vs Piyasa: MDNA geçen yıl % 24.4 oranında getiri sağlayan Canadian Piyasasını aştı.

Fiyat Oynaklığı

Is MDNA's price volatile compared to industry and market?
MDNA volatility
MDNA Average Weekly Movement	9.3%
Biotechs Industry Average Movement	11.2%
Market Average Movement	8.2%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: MDNA son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MDNA 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 16% dan 9% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	16	Fahar Merchant	www.medicenna.com

Bir immünoterapi şirketi olan Medicenna Therapeutics Corp. kanser ve diğer hastalıkların tedavisi için Superkine'lerin ve güçlendirilmiş Superkine'lerin geliştirilmesi ve ticarileştirilmesiyle ilgilenmektedir. Tekrarlayan glioblastoma ve beyin tümörlerinin tedavisi için bir interlökin-4 (IL-4) EC olan bizaxofusp'u (MDNA55) geliştirmektedir. Şirket ayrıca kanserle savaşmak için gereken bağışıklık hücrelerini aktive etmek ve çoğaltmak için IL-2'nin geliştirilmiş bir versiyonu olan MDNA11'i; multipl skleroz ve graft versus host hastalığı gibi otoimmün hastalıklar için bir IL-2 antagonisti olan MDNA209'u; kanser immünoterapilerini tedavi etmek için ikili bir IL-4/IL-13 antagonisti olan MDNA413'ü; çeşitli solid tümörler için maskelenmiş çift fonksiyonlu bir anti-PD1-IL2 Superkine olan MDNA113'ü ve çeşitli tümörler için bir IL-13 Superkine olan MDNA132'yi geliştirmektedir.

Medicenna Therapeutics Corp. Temel Bilgiler Özeti

Medicenna Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MDNA temel i̇stati̇sti̇kler
Piyasa değeri	CA$185.49m
Kazançlar(TTM)	-CA$26.24m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-7.1x

F/K Oranı

MDNA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MDNA gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$26.24m
Kazançlar	-CA$26.24m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.34
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

MDNA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MDNA Stoklara Genel Bakış

Ödüller

Risk Analizi

Medicenna Therapeutics Corp. Rakipler

TSX:EPRX

CA$157.8m

CNSX:DRUG

CA$334.4m

TSX:ONC

CA$125.6m

TSXV:COV

CA$93.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Recent updates

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Medicenna Therapeutics Corp. Announces Management Changes

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?